Ceralasertib

Locations: 🇮🇹
ASST degli Spedali Civili di Brescia, Brescia, Italy
🇮🇹
Azienda Ospedaliero Universitaria Careggi, Firenze, Italy
🇮🇹
IRCCS Ospedale Policlinico San Martino, Genova, Genova, Italy

and more 6 locations

A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy

Phase 2

Active, not recruiting

Conditions: Advanced or Metastatic NSCLC

Interventions: Drug: Ceralasertib
Drug: Durvalumab

First Posted Date: 2023-07-12

Last Posted Date: 2024-11-27

Lead Sponsor: AstraZeneca

Target Recruit Count: 39

Registration Number: NCT05941897

Locations: 🇷🇺
Research Site, St. Petersburg, Russian Federation

Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel

Phase 2

Recruiting

Conditions: Triple Negative Breast Cancer Metastatic

Interventions: Drug: Ceralasertib
Drug: Durvalumab
Drug: Nab-paclitaxel

First Posted Date: 2022-10-17

Last Posted Date: 2023-09-28

Lead Sponsor: IFOM ETS - The AIRC Institute of Molecular Oncology

Target Recruit Count: 37

Registration Number: NCT05582538

Locations: 🇮🇹
Istituto Nazionale dei Tumori IRCCS, Milano, Italy
🇮🇹
Istituto Oncologico Veneto IRCCS, Padova, Italy
🇮🇹
Azienda Ospedaliero Universitaria Maggiore della Carità, Novara, Italy

A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours

Phase 1

Active, not recruiting

Conditions: Advanced Solid Tumours

Interventions: Drug: Ceralasertib
Drug: Durvalumab

First Posted Date: 2022-08-24

Last Posted Date: 2024-11-08

Lead Sponsor: AstraZeneca

Target Recruit Count: 14

Registration Number: NCT05514132

Locations: 🇨🇳
Research Site, Shandong, China

An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies

Phase 1

Completed

Conditions: Advanced Solid Malignancies

Interventions: Drug: Ceralasertib

First Posted Date: 2022-07-22

Last Posted Date: 2024-08-02

Lead Sponsor: AstraZeneca

Target Recruit Count: 12

Registration Number: NCT05469919

Locations: 🇯🇵
Research Site, Chuo-ku, Japan

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

Phase 3

Active, not recruiting

Conditions: Advanced or Metastatic Non-Small Cell Lung Cancer

Interventions: Drug: Ceralasertib
Drug: Docetaxel
Drug: Durvalumab

First Posted Date: 2022-07-11

Last Posted Date: 2024-12-19

Lead Sponsor: AstraZeneca

Target Recruit Count: 594

Registration Number: NCT05450692

Locations: 🇬🇧
Research Site, Wirral, United Kingdom

A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition

Phase 2

Active, not recruiting

Conditions: Melanoma

Interventions: Drug: Ceralasertib
Biological: Durvalumab

First Posted Date: 2021-09-29

Last Posted Date: 2024-11-15

Lead Sponsor: AstraZeneca

Target Recruit Count: 194

Registration Number: NCT05061134

Locations: 🇬🇧
Research Site, Northwood, United Kingdom

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Phase 1

Recruiting

Conditions: Advanced Malignant Solid Neoplasm
Advanced Colon Carcinoma
Advanced Gastroesophageal Junction Adenocarcinoma
Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
Stage III Major Salivary Gland Cancer AJCC v8
Stage III Uterine Corpus Cancer AJCC v8
Stage IV Colorectal Cancer AJCC v8
Unresectable Colorectal Carcinoma
Advanced Gastric Carcinoma
Anatomic Stage IV Breast Cancer AJCC v8

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Drug: Ceralasertib
Procedure: Computed Tomography
Procedure: Echocardiography
Procedure: Multigated Acquisition Scan
Procedure: Positron Emission Tomography
Biological: Trastuzumab Deruxtecan

First Posted Date: 2021-01-12

Last Posted Date: 2024-12-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 51

Registration Number: NCT04704661

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States

and more 18 locations

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Extensive Stage Small Cell Lung Cancer

Interventions: Drug: Cisplatin
Drug: Carboplatin
Drug: Etoposide
Drug: Durvalumab
Drug: Ceralasertib

First Posted Date: 2021-01-07

Last Posted Date: 2024-10-26

Lead Sponsor: Muhammad Furqan

Target Recruit Count: 30

Registration Number: NCT04699838

Locations: 🇺🇸
University of Illinois Medical Center, Chicago, Illinois, United States
🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy